{"id":54158,"date":"2023-02-22T15:07:34","date_gmt":"2023-02-22T14:07:34","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\/"},"modified":"2023-02-22T15:07:34","modified_gmt":"2023-02-22T14:07:34","slug":"lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\/","title":{"rendered":"Lucence Announces Medicare Reimbursement Decision for LiquidHALLMARK\u00ae Assay in Lung Cancer"},"content":{"rendered":"
\n

PALO ALTO, Calif.–(BUSINESS WIRE)–Lucence announced today that Palmetto GBA, a Medicare administrative contractor and leader in evaluating molecular diagnostic technology through its laboratory technology assessment group for the Molecular Diagnostics Services program (MolDX), has finalized a foundational Local Coverage Determination (LCD) for the LiquidHALLMARK <\/b>assay. The LCD covers all nine NCCN guideline-recommended molecular biomarkers in advanced lung cancer patients using LiquidHALLMARK.\n<\/p>\n

<\/a><\/p>\n

\nLiquidHALLMARK is Lucence\u2019s next-generation sequencing (NGS) liquid biopsy test, which helps oncologists identify biomarkers in advanced cancer patients that may inform their treatment decisions. The policy provides for Medicare reimbursement for LiquidHALLMARK tests furnished to most Medicare fee-for-service patients with lung cancer who meet clinical criteria.\n<\/p>\n

\nDr Min-Han Tan, Founding CEO, remarked on the significance of this milestone, saying, \u201cOver 150,000 lung cancer patients over the age of 65 are diagnosed every year in the United States. We are grateful that LiquidHALLMARK will be accessible to more patients in need, and confident that our technology can help inform treatment decisions in the fight against cancer.\u201d\n<\/p>\n

\nThe LiquidHALLMARK test has shown 94.5-100% concordance with tissue-based profiling across nine guideline-recommended biomarkers in the interim results of LIQUIK, a prospective multi-center trial [1]. In this head-to-head study, LiquidHALLMARK identified 24 out of 34 tissue-confirmed guideline-recommended biomarkers, versus 21 by an FDA-approved liquid biopsy test.\n<\/p>\n

\n[1] Dawar et al. (2022 Oct 20-22). Amplicon-Based Liquid Biopsy Platform Complements Tissue Genotyping in Detection of Guideline-Recommended Biomarkers in Metastatic NSCLC [Poster]. International Society of Liquid Biopsy 4th Annual Congress, Miami, United States.\n<\/p>\n

\nAbout Lucence<\/b>\n<\/p>\n

\nLucence is a precision oncology company focused on bringing clarity to cancer care. Our ultrasensitive liquid biopsy tests are based on proprietary AmpliMark\u2122 sequencing technology and data analytics for earlier detection and effective treatment. Lucence operates twin CLIA-licensed, CAP-accredited laboratories in California and Singapore. For more information, visit www.lucence.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nJack Challis
\n
media@lucence.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

PALO ALTO, Calif.–(BUSINESS WIRE)–Lucence announced today that Palmetto GBA, a Medicare administrative contractor and leader in evaluating molecular diagnostic technology through its laboratory technology assessment group for the Molecular Diagnostics Services program (MolDX), has finalized a foundational Local Coverage Determination (LCD) for the LiquidHALLMARK assay. The LCD covers all nine NCCN guideline-recommended molecular biomarkers in … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54158","6":"format-standard","7":"category-industry"},"yoast_head":"\nLucence Announces Medicare Reimbursement Decision for LiquidHALLMARK\u00ae Assay in Lung Cancer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lucence Announces Medicare Reimbursement Decision for LiquidHALLMARK\u00ae Assay in Lung Cancer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"PALO ALTO, Calif.–(BUSINESS WIRE)–Lucence announced today that Palmetto GBA, a Medicare administrative contractor and leader in evaluating molecular diagnostic technology through its laboratory technology assessment group for the Molecular Diagnostics Services program (MolDX), has finalized a foundational Local Coverage Determination (LCD) for the LiquidHALLMARK assay. The LCD covers all nine NCCN guideline-recommended molecular biomarkers in ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-22T14:07:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230222005057\/en\/1717850\/21\/Lucence-Logo-2000px.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Lucence Announces Medicare Reimbursement Decision for LiquidHALLMARK\u00ae Assay in Lung Cancer\",\"datePublished\":\"2023-02-22T14:07:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\\\/\"},\"wordCount\":312,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230222005057\\\/en\\\/1717850\\\/21\\\/Lucence-Logo-2000px.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\\\/\",\"name\":\"Lucence Announces Medicare Reimbursement Decision for LiquidHALLMARK\u00ae Assay in Lung Cancer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230222005057\\\/en\\\/1717850\\\/21\\\/Lucence-Logo-2000px.jpg\",\"datePublished\":\"2023-02-22T14:07:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230222005057\\\/en\\\/1717850\\\/21\\\/Lucence-Logo-2000px.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230222005057\\\/en\\\/1717850\\\/21\\\/Lucence-Logo-2000px.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lucence Announces Medicare Reimbursement Decision for LiquidHALLMARK\u00ae Assay in Lung Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lucence Announces Medicare Reimbursement Decision for LiquidHALLMARK\u00ae Assay in Lung Cancer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Lucence Announces Medicare Reimbursement Decision for LiquidHALLMARK\u00ae Assay in Lung Cancer - Pharma Trend","og_description":"PALO ALTO, Calif.–(BUSINESS WIRE)–Lucence announced today that Palmetto GBA, a Medicare administrative contractor and leader in evaluating molecular diagnostic technology through its laboratory technology assessment group for the Molecular Diagnostics Services program (MolDX), has finalized a foundational Local Coverage Determination (LCD) for the LiquidHALLMARK assay. The LCD covers all nine NCCN guideline-recommended molecular biomarkers in ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-22T14:07:34+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230222005057\/en\/1717850\/21\/Lucence-Logo-2000px.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Lucence Announces Medicare Reimbursement Decision for LiquidHALLMARK\u00ae Assay in Lung Cancer","datePublished":"2023-02-22T14:07:34+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\/"},"wordCount":312,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230222005057\/en\/1717850\/21\/Lucence-Logo-2000px.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\/","url":"https:\/\/pharma-trend.com\/en\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\/","name":"Lucence Announces Medicare Reimbursement Decision for LiquidHALLMARK\u00ae Assay in Lung Cancer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230222005057\/en\/1717850\/21\/Lucence-Logo-2000px.jpg","datePublished":"2023-02-22T14:07:34+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230222005057\/en\/1717850\/21\/Lucence-Logo-2000px.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230222005057\/en\/1717850\/21\/Lucence-Logo-2000px.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/lucence-announces-medicare-reimbursement-decision-for-liquidhallmark-assay-in-lung-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Lucence Announces Medicare Reimbursement Decision for LiquidHALLMARK\u00ae Assay in Lung Cancer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54158","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54158"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54158\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54158"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54158"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54158"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}